FEROS IR 2012 4 10 35 BW 10H} harp, //erurw.ajsmoe.on Acadennie Journal of Serond Miltary Medial University, Ost, 2012,Vol. 88, No,10 Dore 10, 3724/SP. J. 1008, 2012. 01112 ‘BRE BAR, FF) a OD 9 eK a Tr EAE ES A UR BE TOR ACNE aR WP CAR Aeak ae SIS? ah 1, PURGE ICRI RS BEBE DPE EH 102401 2, ERB BEBE WE BM LAF LHC LoOOTL 12+ CARI] PLEIN 1,0 mg/L 0,7 mg/m MG IN 8 OC A 20 9) oe ATS MEL me RE A 2M a BLUE. ok 2008 A 6 FE 2012.95 1 HAR CNR BE Be nin A EK A ASE 26 HEH 16 HAR 1 0 mg/L HEY 510 0.7 mg/m! ARIF, AS Re ALAS He, MEARE PST BESIDE 1.0 mg/m HL 0. 7 mg/m 45 9B 13 OAL 8 BAA 2 ANSP ALEC OFF RCH Ay © LS Le ETE LPO, 05). MINEO A EE BREA aL AAR TROL ER NF PL RE IEEE RCP 0.05), Sea EAE SPE EE AIT 1 © mg/m 0.7 / at AHEM Ha TA EE 1. 0 m/e TO 0.7 ma/u? AL [Seem] Sm Herma AM ERP KM AEA (RM RS] R733 CRAMER] A (HMB) 0258-879N(2012>10-1112-03 Reduced-dose of bortez0 for treatment of elderly patients with multiple myeloma, a clinical study KANG Yau", ZHAO Yue ying! , GUO Mei, YU Chang lin’, QUAO Jina huis HU Kui-x 1, Department of Oncology Aff + SUN Qi- yun! ted Liangxiang Hospital of Cepital Medical University, Beijing 102401 Ching 2, Department of Hematology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, Chine Istract] Objective To discuss the appropriate dose of bortezomib for treatment of eklerly patients with multiple myeloma CMMD by evaluating the curative effects and toxicity of two different doses of hortezomib (1. 0 mg/m! and 0.7 mg/m). Methods Twenty-six MM patients aged =60 years old received reduced-dose of bortezomib from June 2006 to January 2012. with 16 receiving 4 dose of 1.0 mg/m! and the other 10 receiving x dose of 0,7 mg/m®, The curative effects and the adverse events were observed, Results After the first course of trentment 15 patients responsed in the 1.0 mg/m? group rnd 8 i the 0.7 mg/m! group. After the second course of treatment © patients still response in the 1.0 mg/m? group and 5 in the 0,7 mg/m? groups with no significant difference found between the two groups (P>0, 05). The main adverse effects of bortezomib treatment included digestive symptoms, peripheral neuropathy. thrombocytopenia and infection, with no significant Aiference found between the two groups (P>D,05). Conclusion Hortezomi-hased regimens at 1,0 mg/as* and 7 ang fre sale and effective for elderly MM patients ifthe dose 1,0 mg/m? ean not be tolerated; 0,7 mg/m? ean be chosen, [Key words] multiple myelomay bortezomibs dose, aged [Acad J See Mil Med Univ,2012,38(10) : 1142-1144] SMH HAH Cmultple myeloma, MMO JER AEG AEA ALAR), (AF A CIR AOL 1. 8 m/e ‘ - L eL E aA A e me—A OS a A A A HUGS RE ARIE 65.38", BE AP URE Rona Ae REAM ee EARN. TOMS T 1.0 mg/m? £10. 7 mg/m BAA LEROC IT EA MM MET A LL MMC HTT PA, a se Le AE : ce BASH OMMRG RAMEE. CETTE 00 1 atone SP OTOL MM 9 3 LG A BL BLA, EAP RUE FAO EL AE MINA AEA AREA CM 2006 4F 6 FUE 2012 AF BEE (Hmmm) v012 0012 (am) 2120017 [MME] HOO A HEALTH A (2008-3072). Supported by Capital Science Foundation for Medel Development (2008-3072), (RA) ME HWE, Email, kamkang_ shina hotmail com GATE (Corresponding ahr), Tely 010-66871700, Emily sungivun(® yahoo. som. en5 Lo 2 FAI FO A te ee EE +1113 ee ‘ALP EAL BEBE ML 26 LSE He > 80. a iB A MMA He DBE Ra A EE BE A ET I MM ISI Ha 0-2 LLBEAN AML TB HE. NAA 62 ~ 87 oe LAE Wy 10 YT Be eS Bla Hh 19°) SE A 7 hs FEE Te AE 15 (57.796) .16A 38 8 (130. 846) BRED 8 ICL. 5%) sDurie- Salmon 4900. E11 81198 8. I 17 0-3 HES AEA 4.5, 16 DARA 1.0 me/ mn MAPLE ARIST CLO me/ m1) 10 PAA BESE 0. 7 mg/m! AE EAE (0. 7 mg/m? 2), LA AEE BH at TARAS aR mL A ML ‘cAMP PLM,Durie-Salenon Jp HL De Seam 3 Hh FI BALA FRN ALO, 7 mg/m AE RE OB~ 87 oH fA 72 BW BAF 1.0 me/mn a 62~87 Hh (ME 7B IESE ARIF EL(P<0.05), 12 GbR BAST EAN ER OT HL BAMA A. 2; AEF 120050042)1. 0 mg/m" 0.7 mal sn fF 148,11 JEM GE MP UE AE 12 A 5.85 8995 11~12 Fea TWA H 20 mg/d APRA IES VA) 1 AST RR UNA 5 Te nT RAP LS ak AA aE LUA MN 2~30 A Coe 16 1). ROSACEA 2006 SLB PHD NFB EO A A A He CCR) AH VSP SR RR CVGPR) 31898 (PR) eA (SDD KATHE (PD) 8847 BE Coveral response rate,ORR) W486 CR-+ VG- PRYPR, {61157 SCAT 4 Coverall survival OSDI fit ‘FV Or. ee 3 9 OC HA Ef BEE (National Cancer Insti Criteria for Adverse Exents CTCAE) Version 3.0 SE. 14 abSPASE EFA SPSS 17.0 Serb Pt fr MCA SETHE HL CR Fisher RV MORE ARIE CH HHA (0) H 0.05, ne Common Terminolony 2 R 21 AL PALE STIRE T 50 Por EON OE ORIENT. SESH 1.0 may HIER T 38 ATRL AIT «0.7 m/e aL SERRE T 26 191 HDA. 1.0 mg/m’ Al 16 OLE PS DISET A ASTE.S OhnNT T 2 -09r 5 ORI T Ltr 50.7 ma/n' AL 10 ARE 9 OLE A it ee OL ee ee 2.2 sPaHEM 1.0.ma/ LAL 0. 7 mg/m! A A888 1 SPRITES TEM ALAR A 2 RANG AAT 1 ONE AGL CRAPS 3 ODA IAEA VGPR EA 1 PF BERR HO ASA LC 13 A 8 LS 2 LA AE IR NSCs © A 5M, IE Pisher’s MEH RE UAL BAAR P>0.05), 1.0 mg/m AF 3 BLA AES 1 PF ARSED 9 ~ 6 EA ISL WE A 8 OP HE EP A A i AL eh. 3 LA Le a EVENS BREN PRGA 8 LAR ARSE UN REE A E | SPRUIGTTACN SD. SUR 2 NBC TEAM IS IR MR AE HF 8 ML BUEN 2 FP RMR PD, 0.7 mg/m Hf6 1 BU ARSE A hI ALAR CIE ABD 3 Le PD Ht FAR ERE ASE HUE 1. 0 mam? TL EIA PRL 2 EBL AFD PSHE 1 ARE 1 FERED SD, Make is A PTAE MBPS SD. 28 KREB 2.3.1 MER ACLU EE a HAL ALG LAB 1.0 mg/m AAT 12 APF BE HM LS 8h SS hI bo LG 1 a PAR AVE PEL HIER! ALCON ACR. 0.7 mg/m LAT 8 PHP RE HAT HE WIM 8 Pa 9 Pa AL A A, LA IS UAE 39 1~2 Oe HL Bi. Was Mei Le SERIF FEL (P>0. 05). 2.3.2 dose RA MAL GAT 12 PT BE AR 2 SEO 1.0 mayen 5 ASI 2 MRE A Po LI 8 SAGE AST RRL 4 HEH A 1 YEG. 7 n/n? L2H BLA SR 2 LIGHT FY BEE 9 AGH AP RE HL LAUER RN 1 AEE. TL 8 EEE 1.0 ma/m 84 2 fea oe EAB AA et Ma Bk 0 A A A St A LA Bn, IE AP a I BIC Am. 2.3.3 ABSA ADL Ee BEL A AC HA He SEB AS HW A TERE A A ~ 2 1,0-may/ LAN 0,7 mg/m LSPA AE 2 AD a2 oe nL 8 SP 2.3.4 BAR 1.0 mg/mL 0. 7 mg/m LA A REEL Se AT 1 LA 8 A AG 5 A HT A Re LA 8 JE A Ee A EE BL 2 ET A ASFA A MRA Se NEAT HETE, HCO 1.0 mg/en AAT 1 AR PET REP ae PCIE 1 A fe I EL Fest mL RET. 0,7 mag SL 1 I 2.3.5 $218 1.0 mg/m LAM AEE He IEF EY i A RA Re 1, eR aE a THEM FLA MCA A BE 2 RR EH HC. 0.7 a/R ABE IRAE 3B Am A a GT MIM A A AIH LAC ELE MM oF AEG RL DR YE RB 5 WT LT 2 90 FE EE PS A BL 1 BL 60 cL A BAP A at a A ee 4 A A ‘MUBRSCR 0 MM eA a eee ee ee ae eA A 2A, EB+1 BORA EM 2012 6 1B id 68 WEE A BEACH ZU A SHEE CP REE A RE EL — AF FA) TAA RIVA NB PE 948 25 fH IN PUPS BE LALA 2 UC MRR eR AAAI CO LIAL BC, RG ES a Md & eR A A LAE aE TANS AT HR CHE A BL, Dips fo: SP RP SL ee MIME A BEAT TS mg/m A 10 mg/m 4 BE I ASA RO 61.5% 70.0% . MRA APH 38.596 M1 20% «EIB, ATTRA AGT Fe HEEL, LM fete HALL 168 BLA He EERE Se BE 1.8 mg/m’ FO, 7~1. 0 mg/m EAA 0 A A AS AHST MM 1 5 9 5 OA IE A «ELL HF Je ea 9 HH gD RL RE AE ERED tt — JE Xt 0. 70, mg/m V1, 0. mg/L IE He. AHEM ATT 1,0 mg/m 0, 7 mg/m! PAA ‘AUN EPO ANT 26 DLR MIM A PEO. AL AA AIRE PF AF CE EATER 10 mg/m? LP CE WE 67 0.7 mg/m! ALPE MEY 72.2 EW CP 28 AE IW CR eA A A BTN A FEAT 2 NSE RE HH 87 A SS 3 ORLA LA AB MOS ZEB BMI ARAL 0. 7 mg/m RP A SE AP A BAC A ARIS HS. TTR Oh REE OS a REE MEI 1. 0 mg/m S140 0, 7 mg/m BAG ACP 13 OA APS BESS AU 1 Re PH 95 LAL BHF RE RL CREE EMMY PSL EAPC, WS MATL SAE. 0 g/L A 5-0, 7 mg/m EA Ae iE 1,0 mg/m 0 CAPE Ee AMM FADE AN I-AA. MME a BAAR AA APOE CENT MU HEART 0. 7 ma/m® NF ALL. ARTE HRP eH 8 8B ML A EL Ss We > DUIUOAS RRC BE A 5 EL A HSA PIER A HG I LDP AGRE 9 Me 25 OATH A A a Me Se LP TN A A A AE 1.0 emg 891 8 A DB A I gah at, FT A HO A PRE «ETE I NL POR AH (HCE (8D 10 mg/m AAT 1 i ee EBT 9-28 1 4 J RI AB RHE a HO I BE 3 1, 0 mg/m PPOEAHDAET: 0.7 mg/m HAAS ESE ERE 382 AR TSE IEEE MM a AORIL LO m/e A 0. 7 gH EE ME ew Am AR ELIR IAL HE Wm AF EA A EA HB EA, OC mg/m 2A ALOT TE 0. 7 a/R LA SE LR > ALI Sn Aa VE LIMA E 4 Mitahse BEATE POA AW De PAE, (eo % x wt) [1]. Rajkumar $V. Mohie myeloma 2 upeate on diagnosis. risk-steaiieation-and management [I], Am J Hematol 2012. sr.78-8, [2] Lenot! S.Hjorth ML. Westin J.Brinch L Backstrom B.Carlson Ket al Impact of ageon survival after intensive therapy for ‘multiple myelomss a population-based study by the Nordic My oma Study GroupCY]. Br} Haematol. 2008133; 389-396 [5] Maos M V.Hernindes J M.Heminder M T.Gutierres NC. Palomera L, Fuertes Meet al, Bortaomib plus melphalan and prednisone in elderly untreated patien's with multiple myelo- ma updated time-torevents results and prognostic factors for time 1 progression: 11, Haematologiea2008.98;560-585. [HD Curran M PeMeKeage K. Bortezomiby review of is use inp tients with multiple myeloma( J. Drugs.2009.59 859-888 [5] Mateos M V,Oril A.Martinee Lopes I «Gutierrez Ny Teruel A lade Pee Reet al, Bortezomibsmelphalan.and prednisone verss bortezomib, thalidomide, and predaisone as induction therepy followed by maintenance trestment with bortezomib and thai fomide versus bortezomib and predrisone in elderly patients with untreated multiple myeloma; a randomised trial JJ. Lan= «et Oncol 2010611,984-941, (6) SRE oe 18. MLA TAS Me AEM. 9 a ANAEAE,2007 232-285, [7]. Gey F.Palumbo A. Management of older patients with multiple yelomal J], Blood Revs201125:65-73, lumbo A-Matcos M V.Bringhen 8.San Miguel J F; Practical ‘mec tiadreric erent fa enuli Ae sayclcrn een thers py be attenuated in older patents? [J]. ood Rev,2011,254 sito, [9] Fukushima T,Nakemusn T;lwao H-Nakajime AsMiki M,Ssto ‘Teet al, Efficay and safety of bortezomib plus dexamethasone therapy for selractory oF relapsed multiple myelomes once weekly administration of borteromil may reduce the incidence of gastrointestinal adverse events]. Anticancer Res.2011 31 2207-2502, (0) Ma Hh RR eR, 5 LR I AR URIT AT MME eH APRN. ME Fes 2008.88, 1820-1881, [LL] Youn 2 GoJin J+Huang X J+Li YeChen W Ms Liu Z Geet ah Difereat dove combinations of bortezomib and dexamethasone Jn the treatment of elapsed or refractory myelomas an open belsobscevatonel- multi-center study in China[ Chia Med Je 20114124, 2960-2074, CoRR] A